node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
CCL2 | IL2 | ENSP00000225831 | ENSP00000226730 | chemokine (C-C motif) ligand 2; Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis | interleukin 2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells | 0.529 |
CCL2 | P2RX4 | ENSP00000225831 | ENSP00000336607 | chemokine (C-C motif) ligand 2; Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.815 |
CCL21 | P2RX4 | ENSP00000259607 | ENSP00000336607 | chemokine (C-C motif) ligand 21; Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.826 |
CCL21 | P2RY12 | ENSP00000259607 | ENSP00000307259 | chemokine (C-C motif) ligand 21; Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs | purinergic receptor P2Y, G-protein coupled, 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Involved in platelet aggregation | 0.908 |
CCL21 | P2RY13 | ENSP00000259607 | ENSP00000320376 | chemokine (C-C motif) ligand 21; Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs | purinergic receptor P2Y, G-protein coupled, 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system | 0.900 |
GATA2 | P2RX4 | ENSP00000345681 | ENSP00000336607 | GATA binding protein 2; Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5’-AGATAG-3’ | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.802 |
IL2 | CCL2 | ENSP00000226730 | ENSP00000225831 | interleukin 2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells | chemokine (C-C motif) ligand 2; Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis | 0.529 |
IL2 | P2RX4 | ENSP00000226730 | ENSP00000336607 | interleukin 2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.801 |
IRF5 | P2RX4 | ENSP00000349770 | ENSP00000336607 | interferon regulatory factor 5 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.804 |
P2RX4 | CCL2 | ENSP00000336607 | ENSP00000225831 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | chemokine (C-C motif) ligand 2; Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis | 0.815 |
P2RX4 | CCL21 | ENSP00000336607 | ENSP00000259607 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | chemokine (C-C motif) ligand 21; Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs | 0.826 |
P2RX4 | GATA2 | ENSP00000336607 | ENSP00000345681 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | GATA binding protein 2; Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5’-AGATAG-3’ | 0.802 |
P2RX4 | IL2 | ENSP00000336607 | ENSP00000226730 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | interleukin 2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells | 0.801 |
P2RX4 | IRF5 | ENSP00000336607 | ENSP00000349770 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | interferon regulatory factor 5 | 0.804 |
P2RX4 | P2RY1 | ENSP00000336607 | ENSP00000304767 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | purinergic receptor P2Y, G-protein coupled, 1; Receptor for extracellular adenine nucleotides such as ATP and ADP. In platelets binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and probably to platelet aggregation | 0.769 |
P2RX4 | P2RY12 | ENSP00000336607 | ENSP00000307259 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | purinergic receptor P2Y, G-protein coupled, 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Involved in platelet aggregation | 0.770 |
P2RX4 | P2RY13 | ENSP00000336607 | ENSP00000320376 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | purinergic receptor P2Y, G-protein coupled, 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system | 0.767 |
P2RX4 | P2RY2 | ENSP00000336607 | ENSP00000310305 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | purinergic receptor P2Y, G-protein coupled, 2; Receptor for ATP and UTP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP | 0.757 |
P2RX4 | PLA2G1B | ENSP00000336607 | ENSP00000312286 | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | phospholipase A2, group IB (pancreas); PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules | 0.773 |
P2RY1 | P2RX4 | ENSP00000304767 | ENSP00000336607 | purinergic receptor P2Y, G-protein coupled, 1; Receptor for extracellular adenine nucleotides such as ATP and ADP. In platelets binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and probably to platelet aggregation | purinergic receptor P2X, ligand-gated ion channel, 4; Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin | 0.769 |